Anti-MCSP antibodies

Patent metadata

Field	Value
Publication number	US-9309306-B2
Application number	US-201213590904-A
Country	US
Kind code	B2
Filing date	Aug 21, 2012
Priority date	Aug 23, 2011
Publication date	Apr 12, 2016
Grant date	Apr 12, 2016

Abstract

The invention provides anti-MCSP antibodies and methods of using the same.

First claim

What is claimed is:

1. An isolated antibody that binds to human Melanoma chondroitin sulfate proteoglycan (MCSP) wherein the antibody comprises (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO: 18; and (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO: 16.

2. The antibody of claim 1 , further comprising (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO: 13; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

3. An isolated antibody that binds to human Melanoma chondroitin sulfate proteoglycan (MCSP), wherein the antibody comprises (a) HVR-L1 comprising the amino acid sequence of SEQ ID NO:13; (b) HVR-L2 comprising the amino acid sequence of SEQ ID NO: 11; and (c) HVR-L3 comprising the amino acid sequence of SEQ ID NO: 12.

4. The antibody of claim 2 , comprising (a) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 32; (b) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 31; or (c) a VH sequence as in (a) and a VL sequence as in (b).

5. The antibody of claim 4 , comprising a VH sequence of SEQ ID NO: 32.

6. The antibody of claim 4 , comprising a VL sequence of SEQ ID NO: 31.

7. The antibody of claim 4 , comprising a VH sequence of SEQ ID NO: 32 and a VL sequence of SEQ ID NO: 31.

8. An immunoconjugate comprising the antibody of claim 2 and a cytotoxic agent.

9. A pharmaceutical formulation comprising the antibody of claim 2 and a pharmaceutically acceptable carrier.

10. The antibody of claim 2 , wherein the antibody is a monoclonal, humanized, or chimeric antibody.

11. The antibody of claim 2 , wherein the antibody is a full-length IgG class antibody.

12. The antibody of claim 11 , wherein the antibody has been glycoengineered to modify the oligosaccharides in the Fc region and wherein the antibody has increased ADCC effector function as compared to an non-glycoengineered antibody.

13. The antibody of claim 12 , wherein the Fc region has a reduced number of fucose residues as compared to the nonglycoengineered antibody.

14. The antibody of claim 12 , wherein the antibody has an increased ratio of GlcNAc residues to fucose residues in the Fc region compared to the non-glycoengineered antibody.

15. The antibody of claim 12 , wherein the Fc region has an increased proportion of bisected oligosaccharides as compared to the non-glycoengineered antibody.

16. The antibody of claim 7 , wherein the antibody is a monoclonal, humanized, or chimeric antibody.

17. The antibody of claim 7 , wherein the antibody is a full-length IgG class antibody.

18. The antibody of claim 17 , wherein the antibody has been glycoengineered to modify the oligosaccharides in the Fc region and wherein the antibody has increased ADCC effector function as compared to an non-glycoengineered antibody.

19. The antibody of claim 18 , wherein the Fc region has a reduced number of fucose residues as compared to the nonglycoengineered antibody.

20. The antibody of claim 18 , wherein the antibody has an increased ratio of GlcNAc residues to fucose residues in the Fc region compared to the non-glycoengineered antibody.

21. The antibody of claim 18 , wherein the Fc region has an increased proportion of bisected oligosaccharides as compared to the non-glycoengineered antibody.

Assignees

• Freytag Olivier
• Georges Guy
• Moessner Ekkehard
• Mundigl Olaf
• Tuffin Gérald
• Umana Pablo
• Roche Glycart Ag

Inventors

• Freytag Olivier
• Georges Guy
• Moessner Ekkehard
• Mundigl Olaf
• Tuffin Gérald
• Umana Pablo

Classifications

• A61K2039/505

  comprising antibodies · CPC title

• C07K2317/24

  containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title

• C07K16/18 Primary

  against material from animals or humans · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• A61P35/02

  specific for leukemia · CPC title